IMV News and Press, IMV Inc. From 11/12/22

IMV, Inc. (IMV) Q3 2022 Earnings Conference Call November 11, 2022 08:00 AM ET Company Participants Brittany Davison - Chief Accounting Officer Andrew Hall - Chief Executive Officer Jeremy Graff - Chief Scientific Officer Conference Call Participants ...

The following slide deck was published by IMV Inc. in conjunction with their 2022 Q3 earnings call. For further details see: IMV Inc. 2022 Q3 - Results - Earnings Call Presentation

IMV press release ( NASDAQ: IMV ): Q3 GAAP EPS of -$0.11 beats by $0.03 . On September 30, 2022, the Company had cash and cash equivalents of $21.7 million and working capital of $18.2 million, compared with $38.6 million and $37.1 million, respectively at December 3...

IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX ® platform to treat solid and hematologic cancers, today announced its f...

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX ® platform to treat solid and hematologic cancers, today announced that it will hold a conference call and webcast on Friday, November 11, 2022...

Enrollment has accelerated in the last quarter, reflecting enthusiasm for this novel treatment option Data to be presented at a scientific conference in early 2023 IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of ...

IMV ( NASDAQ: IMV ) said it was undertaking a reorganization and reducing its workforce by nearly one third. The company will focus on its DPX platform and advance its lead DPX asset Maveropepimut-S (MVP-S), IMV said in a Sept. 15 press release. IMV ...

Reorganization enhances organizational focus on strategic priorities Clinical update on DLBCL patients in Phase 2B VITALIZE trial to be provided in September Appointment of Dr. Saman Maleki to Board of Directors Brittany Davison promoted to Chief Accounting Off...

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX ® platform to treat solid and hematologic cancers, today announced that members of IMV’s executive management team will be presenting at...

IMV Inc. (IMV) Q2 2022 Earnings Conference Call August 11, 2022 08:00 ET Company Participants Brittany Davison - Senior Vice President of Finance Andrew Hall - Chief Executive Officer Jeremy Graff - Chief Medical Officer Conference Call Participants ...